Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood protein clues could predict sepsis in cancer patients

NCT ID NCT07277387

Knowledge-focused Sponsor: Instituto de Investigación Biomédica de Salamanca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at blood samples from 350 adults with blood cancer who develop a fever and have very low white blood cells (a condition called febrile neutropenia). The goal is to find patterns of proteins in the blood that can predict if a patient will develop serious complications like sepsis. By identifying these protein patterns early, doctors may be able to treat patients more quickly and effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 350 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Oncohematologic Patients With Febrile Neutropenia

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (≥18 years). * Written informed consent provided by patient or legal representative. * Diagnosis of hematologic malignancy under induction chemotherapy, post-allogeneic hematopoietic stem cell transplantation, or CAR-T therapy. * High-risk febrile neutropenia (ANC ≤ 100 cells/mm³, expected duration ≥ 7 days, or significant comorbidities). * Fever defined as oral temperature ≥38.3 °C once or ≥38.0 °C for ≥1 hour. * Hospitalized or requiring immediate admission at the time of FN diagnosis. ´- Initial uncomplicated clinical presentation, with no previous infection or colonization by multidrug-resistant bacteria. * Eligible for initial monotherapy with broad-spectrum empirical antibiotic. * Availability for serial plasma sampling and clinical follow-up. Exclusion Criteria: * Age \<18 years. * Low-risk FN according to MASCC/CISNE criteria. * Initial sample collected after antibiotic administration. * Decline or inability to provide informed consent. * Any condition preventing safe participation or reliable sample collection. * Fever induced by noninfectious causes (considered as adjustment factor, not exclusion).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Febrile neutropenia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Febrile Neutropenia hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm Sepsis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Febrile neutropenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Complejo Asistencial Universitario de Salamanca

    RECRUITING

    Salamanca, Salamanca, 37007, Spain

  • Hospital Universitari Vall d'Hebron

    NOT_YET_RECRUITING

    Barcelona, Barcelona, Spain

  • Hospital Universitario Virgen Macarena

    NOT_YET_RECRUITING

    Seville, Sevilla, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.